Introduksjon
Denne siden gir en grundig analyse av den kjente historikken for insidernes handelsaktiviteter for Jeffrey Chodakewitz. Insidere er ledere, direktører eller betydelige investorer i et selskap. Det er ulovlig for insidere å gjøre handler i deres selskaper basert på spesifikke, ikke-offentlig informasjon. Dette betyr ikke at det er ulovlig for dem å gjøre noen handler i deres egne selskaper. Imidlertid må de rapportere alle handler til SEC via et skjema 4. Til tross for disse begrensningene, antyder akademisk forskning at insidere - generelt sett - har en tendens til å overgå markedet i sine egne selskaper.
Gjennomsnittlig handelslønnsomhet
Den gjennomsnittlige handelslønnsomheten er den gjennomsnittlige avkastningen av alle åpne markedskjøp gjort av insideren de siste tre årene. For å beregne dette, undersøker vi hvert eneste åpne marked, uplanlagte kjøp som er gjort av insideren, men dette inkluderer ikke alle handler som ble markert som en del av en 10b5-1 handelsplan. Vi beregner deretter gjennomsnittlig ytelse av disse handlene over 3, 6 og 12 måneder, gjennomsnittlig hver av disse varighetene for å generere en endelig ytelsesmåling for hver handel. Til slutt,
Dersom lønnsomheten for denne interne handelen er "N/A", har enten den interne personen ikke gjort noen åpen-markeds kjøp de siste tre årene, eller så er handlene for nylig til å beregne en pålitelig prestasjonsmåler.
Oppdateringsfrekvens: Daglig
Selskaper med rapporterte insiderposisjoner
SEC-arkiveringene indikerer at Jeffrey Chodakewitz har rapporterte beholdninger av handler i følgende selskaper:
Verdipapir | Navn | Siste rapporterte høydepunkter |
---|---|---|
US:SDGR / Schrödinger, Inc. | Director | 17 247 |
US:ACET / Adicet Bio, Inc. | Director | 17 700 |
US:PRAX / Praxis Precision Medicines, Inc. | Director | 22 753 |
Director | 16 500 | |
US:VRTX / Vertex Pharmaceuticals Incorporated | EVP GMDA, CMO | 69 663 |
Hvordan tolke diagrammene
De følgende diagrammene viser aksjens ytelse etter hver åpen markedstransaksjon som ikke var planlagt, utført av Jeffrey Chodakewitz. Ikke-planlagte handler er handler som ikke ble gjort som en del av en 10b5-1 handelsplan. Aksjeytelsen er kartlagt som kumulativ prosentendring i aksjekursen. For eksempel, hvis en innsidehandel ble gjort 1. januar 2019, vil diagrammet vise daglig prosentendring for verdipapiret til dagens dato. Dersom aksjeprisen går fra $10 til $15 i løpet av denne tiden, vil den kumulative prosentendringen i aksjeprisen være 50%. En endring i prisen fra $10 til $20 vil være 100%, og en endring i prisen fra $10 til $5 vil være - 50%.
Til syvende og sist er målet vårt å avgjøre hvor tett insidernes handler korrelerer med overavkastninger (positiv eller negativ) i aksjekursen for å se om insidere timer sine handler for å tjene på intern informasjon. Se for deg en situasjon der en insider gjør dette. I denne situasjonen, forventer vi enten (a) positive avkastninger etter kjøp, eller (b) negative avkastninger etter salg. I tilfelle (a) KJØP-diagrammet ville vise en serie av oppadgående kurver, som indikerer positive avkastninger etter hver kjøpstransaksjon. I tilfelle (b) ville SALG-diagrammet vise en serie av nedadgående kurver, som indikerer negative avkastninger etter hver salgstransaksjon.
Imidlertid er dette alene ikke nok til å dra konklusjoner. Hvis, for eksempel, aksjeprisen for selskapet steg jevnt over mange år uten å følge en syklisk trend, ville vi forventet at alle postkjøpsdiagrammer skal ha en stigende trend. På samme måte vil ikke-sykliske nedganger over mange år resultere i nedadgående trend i post-trade diagrammer. Ingen av disse diagrammene ville antyde aktiviteter som insidertrening.
Den sterkeste indikatoren ville vært en situasjon der aksjekursen var ekstremt syklisk, og det var både positive signaler i KJØPSdiagrammet og negative plot i SALGSdiagrammet. Denne situasjonen ville vært sterkt antydende om en insider som timet handler til sin økonomiske fordel.
Internkjøp PRAX / Praxis Precision Medicines, Inc. - Analyse av kortsiktig fortjeneste
I denne seksjonen analyserer vi lønnsomheten av hvert uplanlagt, åpen-marked internsalg som er gjort i PRAX / Praxis Precision Medicines, Inc.. Denne analysen hjelper til å forstå om den interne personen regelmessig genererer unormale avkastninger, og er verdt å følge. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til maks |
Pris ved maks |
Maks fortjeneste ($) |
Maks fortjeneste (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internhandel PRAX / Praxis Precision Medicines, Inc. - Analyse av kortsiktig tap
I denne seksjonen analyserer vi unngåelsen av kortsiktig tap for hvert uplanlagt, åpen-marked internsalg som er gjort i PRAX / Praxis Precision Medicines, Inc.. Et jevnt mønster av tap unngåelse kan antyde at fremtidige salgstransaksjoner kan forutsi nedgang i pris. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til min |
Pris ved min |
Maks tap unngått ($) |
Maks tap unngått (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internkjøp SDGR / Schrödinger, Inc. - Analyse av kortsiktig fortjeneste
I denne seksjonen analyserer vi lønnsomheten av hvert uplanlagt, åpen-marked internsalg som er gjort i PRAX / Praxis Precision Medicines, Inc.. Denne analysen hjelper til å forstå om den interne personen regelmessig genererer unormale avkastninger, og er verdt å følge. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til maks |
Pris ved maks |
Maks fortjeneste ($) |
Maks fortjeneste (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internhandel SDGR / Schrödinger, Inc. - Analyse av kortsiktig tap
I denne seksjonen analyserer vi unngåelsen av kortsiktig tap for hvert uplanlagt, åpen-marked internsalg som er gjort i PRAX / Praxis Precision Medicines, Inc.. Et jevnt mønster av tap unngåelse kan antyde at fremtidige salgstransaksjoner kan forutsi nedgang i pris. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til min |
Pris ved min |
Maks tap unngått ($) |
Maks tap unngått (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Innsidernes handelshistorikk
Tabellen viser den komplette listen over innsidehandler gjort av Jeffrey Chodakewitz som avslørt til Securies Exchange Comission (SEC).
Fildato | Transaksjonsdato | Skjema | Ticker | Verdipapir | Kode | Aksjer | Gjenværende aksjer | Prosent endring |
Aksje pris |
Transaksjons verdi |
Gjenværende verdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-06-20 |
|
4 | SDGR |
Schrodinger, Inc.
Common Stock |
A - Award | 5 997 | 17 247 | 53,31 | ||||
2025-06-13 |
|
4 | ACET |
Adicet Bio, Inc.
Common Stock |
A - Award | 5 900 | 17 700 | 50,00 | ||||
2024-06-20 |
|
4 | SDGR |
Schrodinger, Inc.
Common Stock |
A - Award | 5 000 | 11 250 | 80,00 | ||||
2024-06-07 |
|
4 | ACET |
Adicet Bio, Inc.
Common Stock |
A - Award | 5 900 | 11 800 | 100,00 | ||||
2023-06-16 |
|
4 | SDGR |
Schrodinger, Inc.
Common Stock |
A - Award | 6 250 | 6 250 | |||||
2023-06-02 |
|
4 | ACET |
Adicet Bio, Inc.
Common Stock |
A - Award | 5 900 | 5 900 | |||||
2022-05-27 |
|
4 | PRAX |
Praxis Precision Medicines, Inc.
Stock Option (Right to Buy) |
A - Award | 22 753 | 22 753 | |||||
2021-06-21 |
|
4 | SDGR |
Schrodinger, Inc.
Stock Option (right to buy) |
A - Award | 8 736 | 8 736 | |||||
2021-05-04 |
|
4 | ACET |
Adicet Bio, Inc.
Stock Option (Right to Buy) |
A - Award | 18 500 | 18 500 | |||||
2021-04-15 |
|
4 | PRAX |
Praxis Precision Medicines, Inc.
Stock Option (Right to Buy) |
A - Award | 38 579 | 38 579 | |||||
2020-09-17 |
|
4 | ACET |
Adicet Bio, Inc.
Stock Option (Right to Buy) |
A - Award | 30 000 | 30 000 | |||||
2020-06-05 |
|
4 | TORC |
resTORbio, Inc.
Stock Option (Right to Buy) |
A - Award | 14 414 | 14 414 | |||||
2020-05-04 |
|
4 | SDGR |
Schrodinger, Inc.
Stock Option (right to buy) |
A - Award | 25 216 | 25 216 | |||||
2019-06-11 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Stock option (right to buy) |
A - Award | 16 500 | 16 500 | |||||
2019-05-09 |
|
4 | TORC |
resTORbio, Inc.
Stock Option (Right to Buy) |
A - Award | 14 414 | 14 414 | |||||
2018-08-15 |
|
4 | TORC |
resTORbio, Inc.
Stock Option (Right to Buy) |
A - Award | 28 828 | 28 828 | |||||
2018-06-01 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Stock option (right to buy) |
A - Award | 12 500 | 12 500 | |||||
2018-02-14 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −300 | 69 663 | −0,43 | 153,69 | −46 107 | 10 706 506 |
2018-02-14 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −400 | 69 963 | −0,57 | 152,62 | −61 048 | 10 677 753 |
2018-02-14 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 022 | 70 363 | −2,79 | 151,26 | −305 848 | 10 643 107 |
2018-02-14 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 100 | 72 385 | −1,50 | 150,47 | −165 517 | 10 891 771 |
2018-02-14 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 300 | 73 485 | −1,74 | 149,21 | −193 973 | 10 964 697 |
2018-02-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
A - Award | 23 479 | 23 479 | |||||
2018-02-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 10 125 | 74 785 | 15,66 | ||||
2018-02-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 12 136 | 64 660 | 23,11 | ||||
2018-02-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −3 594 | 14 375 | −20,00 | ||||
2018-02-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −100 | 52 524 | −0,19 | 164,71 | −16 471 | 8 651 228 |
2018-02-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −900 | 52 624 | −1,68 | 164,12 | −147 708 | 8 636 651 |
2018-02-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −400 | 53 524 | −0,74 | 162,94 | −65 176 | 8 721 201 |
2018-02-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −500 | 53 924 | −0,92 | 161,51 | −80 755 | 8 709 265 |
2018-02-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −500 | 54 424 | −0,91 | 160,50 | −80 250 | 8 735 052 |
2018-02-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −700 | 54 924 | −1,26 | 159,62 | −111 734 | 8 766 969 |
2018-02-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −494 | 55 624 | −0,88 | 158,32 | −78 210 | 8 806 392 |
2018-02-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 3 594 | 56 118 | 6,84 | 109,14 | 392 249 | 6 124 719 | |
2018-02-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −1 796 | 14 368 | −11,11 | ||||
2018-02-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −100 | 52 524 | −0,19 | 169,49 | −16 949 | 8 902 293 |
2018-02-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −100 | 52 624 | −0,19 | 168,06 | −16 806 | 8 843 989 |
2018-02-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −996 | 52 724 | −1,85 | 166,10 | −165 436 | 8 757 456 |
2018-02-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −600 | 53 720 | −1,10 | 165,23 | −99 138 | 8 876 156 |
2018-02-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 1 796 | 54 320 | 3,42 | 91,05 | 163 526 | 4 945 836 | |
2018-02-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 900 | 52 524 | −3,49 | 167,44 | −318 136 | 8 794 619 |
2018-01-17 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −1 719 | 3 438 | −33,33 | ||||
2018-01-17 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −300 | 54 424 | −0,55 | 159,04 | −47 712 | 8 655 593 |
2018-01-17 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −900 | 54 724 | −1,62 | 157,54 | −141 786 | 8 621 219 |
2018-01-17 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −519 | 55 624 | −0,92 | 155,80 | −80 860 | 8 666 219 |
2018-01-17 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 1 719 | 56 143 | 3,16 | 96,87 | 166 520 | 5 438 572 | |
2018-01-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −3 438 | 0 | −100,00 | ||||
2018-01-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −863 | 54 424 | −1,56 | 152,80 | −131 866 | 8 315 987 |
2018-01-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 600 | 55 287 | −2,81 | 152,06 | −243 296 | 8 406 941 |
2018-01-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −675 | 56 887 | −1,17 | 150,87 | −101 837 | 8 582 542 |
2018-01-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −300 | 57 562 | −0,52 | 149,65 | −44 895 | 8 614 153 |
2018-01-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 3 438 | 57 862 | 6,32 | 73,51 | 252 727 | 4 253 436 | |
2017-11-06 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −3 594 | 17 969 | −16,67 | ||||
2017-11-06 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −3 594 | 54 424 | −6,19 | 144,69 | −520 016 | 7 874 609 |
2017-11-06 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 3 594 | 58 018 | 6,60 | 109,14 | 392 249 | 6 332 085 | |
2017-11-06 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −1 796 | 16 164 | −10,00 | ||||
2017-11-06 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −300 | 54 424 | −0,55 | 145,89 | −43 767 | 7 939 917 |
2017-11-06 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 096 | 54 724 | −1,96 | 144,89 | −158 799 | 7 928 960 |
2017-11-06 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −400 | 55 820 | −0,71 | 143,54 | −57 416 | 8 012 403 |
2017-11-06 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 1 796 | 56 220 | 3,30 | 91,05 | 163 526 | 5 118 831 | |
2017-10-31 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −200 | 54 424 | −0,37 | 149,34 | −29 868 | 8 127 680 |
2017-10-31 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 400 | 54 624 | −2,50 | 148,40 | −207 760 | 8 106 202 |
2017-10-31 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −3 400 | 56 024 | −5,72 | 147,75 | −502 350 | 8 277 546 |
2017-10-31 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −4 700 | 59 424 | −7,33 | 146,52 | −688 644 | 8 706 804 |
2017-10-31 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −19 016 | 64 124 | −22,87 | 145,26 | −2 762 264 | 9 314 652 |
2017-10-31 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −25 784 | 83 140 | −23,67 | 144,46 | −3 724 757 | 12 010 404 |
2017-10-31 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −4 100 | 108 924 | −3,63 | 143,46 | −588 186 | 15 626 237 |
2017-10-31 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 400 | 113 024 | −1,22 | 142,38 | −199 332 | 16 092 357 |
2017-10-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −1 718 | 5 157 | −24,99 | ||||
2017-10-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −300 | 114 424 | −0,26 | 157,38 | −47 214 | 18 008 049 |
2017-10-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −300 | 114 724 | −0,26 | 155,92 | −46 776 | 17 887 766 |
2017-10-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −818 | 115 024 | −0,71 | 154,76 | −126 594 | 17 801 114 |
2017-10-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −300 | 115 842 | −0,26 | 153,42 | −46 026 | 17 772 480 |
2017-10-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 1 718 | 116 142 | 1,50 | 96,87 | 166 423 | 11 250 676 | |
2017-10-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −3 437 | 3 438 | −49,99 | ||||
2017-10-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −600 | 114 424 | −0,52 | 152,62 | −91 572 | 17 463 391 |
2017-10-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 443 | 115 024 | −1,24 | 151,82 | −219 076 | 17 462 944 |
2017-10-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 394 | 116 467 | −1,18 | 151,04 | −210 550 | 17 591 176 |
2017-10-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 3 437 | 117 861 | 3,00 | 73,51 | 252 654 | 8 663 962 | |
2017-08-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −3 594 | 21 563 | −14,29 | ||||
2017-08-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −500 | 114 424 | −0,44 | 155,15 | −77 575 | 17 752 884 |
2017-08-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 494 | 114 924 | −2,12 | 154,21 | −384 600 | 17 722 430 |
2017-08-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −600 | 117 418 | −0,51 | 153,29 | −91 974 | 17 999 005 |
2017-08-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 3 594 | 118 018 | 3,14 | 109,14 | 392 249 | 12 880 485 | |
2017-08-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −1 796 | 17 960 | −9,09 | ||||
2017-08-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −296 | 114 424 | −0,26 | 156,24 | −46 247 | 17 877 606 |
2017-08-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −400 | 114 720 | −0,35 | 154,89 | −61 956 | 17 768 981 |
2017-08-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −600 | 115 120 | −0,52 | 153,93 | −92 358 | 17 720 422 |
2017-08-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −500 | 115 720 | −0,43 | 152,50 | −76 250 | 17 647 300 |
2017-08-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 1 796 | 116 220 | 1,57 | 91,05 | 163 526 | 10 581 831 | |
2017-07-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 336 | 114 424 | −1,15 | 162,04 | −216 485 | 18 541 265 |
2017-07-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −3 464 | 115 760 | −2,91 | 161,38 | −559 020 | 18 681 349 |
2017-07-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −400 | 119 224 | −0,33 | 159,85 | −63 940 | 19 057 956 |
2017-07-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 000 | 119 624 | −0,83 | 158,92 | −158 920 | 19 010 646 |
2017-07-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −700 | 120 624 | −0,58 | 158,08 | −110 656 | 19 068 242 |
2017-07-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −32 343 | 25 157 | −56,25 | ||||
2017-07-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −6 303 | 6 875 | −47,83 | ||||
2017-07-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −39 833 | 121 324 | −24,72 | 161,00 | −6 413 113 | 19 533 164 |
2017-07-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 32 343 | 161 157 | 25,11 | 109,14 | 3 529 915 | 17 588 675 | |
2017-07-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 6 303 | 128 814 | 5,14 | 96,87 | 610 572 | 12 478 212 | |
2017-07-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −573 | 13 178 | −4,17 | ||||
2017-07-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −100 | 122 511 | −0,08 | 130,96 | −13 096 | 16 044 041 |
2017-07-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −473 | 122 611 | −0,38 | 129,61 | −61 306 | 15 891 612 |
2017-07-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 573 | 123 084 | 0,47 | 96,87 | 55 507 | 11 923 147 | |
2017-07-06 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −3 438 | 6 875 | −33,34 | ||||
2017-07-06 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 216 | 122 511 | −0,98 | 128,57 | −156 341 | 15 751 239 |
2017-07-06 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 222 | 123 727 | −1,76 | 127,38 | −283 038 | 15 760 345 |
2017-07-06 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 3 438 | 125 949 | 2,81 | 73,51 | 252 727 | 9 258 511 | |
2017-06-23 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −5 157 | 8 594 | −37,50 | ||||
2017-06-23 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −5 157 | 122 511 | −4,04 | 132,87 | −685 211 | 16 278 037 |
2017-06-23 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 5 157 | 127 668 | 4,21 | 96,87 | 499 559 | 12 367 199 | |
2017-06-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −5 155 | 18 908 | −21,42 | ||||
2017-06-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −5 155 | 122 511 | −4,04 | 126,87 | −654 015 | 15 542 971 |
2017-06-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 5 155 | 127 666 | 4,21 | 96,87 | 499 365 | 12 367 005 | |
2017-06-01 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Stock option (right to buy) |
A - Award | 12 500 | 12 500 | |||||
2017-05-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −8 979 | 19 756 | −31,25 | ||||
2017-05-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −8 979 | 122 511 | −6,83 | 121,05 | −1 086 908 | 14 829 957 |
2017-05-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 8 979 | 131 490 | 7,33 | 91,05 | 817 538 | 11 972 164 | |
2017-04-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | −8 021 | 10 313 | −43,75 | ||||
2017-04-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −8 021 | 122 511 | −6,14 | 114,00 | −914 394 | 13 966 254 |
2017-04-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 8 021 | 130 532 | 6,55 | 73,51 | 589 624 | 9 595 407 | |
2017-04-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −2 291 | 18 334 | −11,11 | ||||
2017-04-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −200 | 122 511 | −0,16 | 110,09 | −22 018 | 13 487 236 |
2017-04-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −600 | 122 711 | −0,49 | 109,32 | −65 592 | 13 414 767 |
2017-04-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 491 | 123 311 | −1,19 | 108,50 | −161 774 | 13 379 244 |
2017-04-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 2 291 | 124 802 | 1,87 | 73,51 | 168 411 | 9 174 195 | |
2017-03-31 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −13 750 | 20 625 | −40,00 | ||||
2017-03-31 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −13 750 | 122 511 | −10,09 | 106,65 | −1 466 438 | 13 065 798 |
2017-03-31 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 13 750 | 136 261 | 11,22 | 73,51 | 1 010 762 | 10 016 546 | |
2017-02-15 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −5 122 | 122 511 | −4,01 | 87,67 | −449 046 | 10 740 539 |
2017-02-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
A - Award | 24 852 | 24 852 | |||||
2017-02-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 12 136 | 127 633 | 10,51 | ||||
2017-02-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 4 794 | 115 497 | 4,33 | 0,01 | 48 | 1 155 | |
2017-02-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 500 | 110 703 | −1,34 | 85,91 | −128 865 | 9 510 495 |
2017-02-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −400 | 112 203 | −0,36 | 85,08 | −34 032 | 9 546 231 |
2016-06-10 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Stock option (right to buy) |
A - Award | 10 000 | 10 000 | |||||
2016-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 28 735 | 28 735 | |||||
2016-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 275 | 112 603 | −1,12 | 91,80 | −117 045 | 10 336 955 |
2016-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 100 | 113 878 | −0,96 | 90,89 | −99 979 | 10 350 371 |
2016-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 14 416 | 114 978 | 14,34 | 0,01 | 144 | 1 150 | |
2015-11-20 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −10 315 | 30 938 | −25,00 | ||||
2015-11-20 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −10 315 | 100 562 | −9,30 | 130,00 | −1 340 950 | 13 073 060 |
2015-11-20 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 10 315 | 110 877 | 10,26 | 73,51 | 758 256 | 8 150 568 | |
2015-07-23 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option |
A - Award | 34 000 | 34 000 | |||||
2015-07-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −2 291 | 41 253 | −5,26 | ||||
2015-07-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 297 | 100 562 | −1,27 | 130,63 | −169 427 | 13 136 414 |
2015-07-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −100 | 101 859 | −0,10 | 129,54 | −12 954 | 13 194 815 |
2015-07-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −500 | 101 959 | −0,49 | 128,12 | −64 060 | 13 062 987 |
2015-07-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −394 | 102 459 | −0,38 | 126,69 | −49 916 | 12 980 531 |
2015-07-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 2 291 | 102 853 | 2,28 | 73,51 | 168 411 | 7 560 724 | |
2015-06-11 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Stock option (right to buy) |
A - Award | 10 000 | 10 000 | |||||
2015-04-06 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −2 291 | 43 544 | −5,00 | ||||
2015-04-06 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −545 | 100 562 | −0,54 | 116,70 | −63 602 | 11 735 585 |
2015-04-06 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 746 | 101 107 | −1,70 | 115,12 | −201 000 | 11 639 438 |
2015-04-06 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 2 291 | 102 853 | 2,28 | 73,51 | 168 411 | 7 560 724 | |
2015-02-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
A - Award | 57 500 | 57 500 | |||||
2015-02-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 17 250 | 100 562 | 20,71 | 0,01 | 172 | 1 006 | |
2015-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −100 | 83 312 | −0,12 | 110,85 | −11 085 | 9 235 135 |
2015-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −788 | 83 412 | −0,94 | 109,80 | −86 522 | 9 158 638 |
2015-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −300 | 84 200 | −0,36 | 108,64 | −32 592 | 9 147 488 |
2015-01-06 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −2 291 | 45 835 | −4,76 | ||||
2015-01-06 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −991 | 84 500 | −1,16 | 123,12 | −122 012 | 10 403 640 |
2015-01-06 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 200 | 85 491 | −1,38 | 122,35 | −146 820 | 10 459 824 |
2015-01-06 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −100 | 86 691 | −0,12 | 119,03 | −11 903 | 10 318 830 |
2015-01-06 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 2 291 | 86 791 | 2,71 | 73,51 | 168 411 | 6 380 006 | |
2014-11-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 75 000 | 84 500 | 789,47 | 0,01 | 750 | 845 | |
2014-10-30 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −3 438 | 48 126 | −6,67 | ||||
2014-10-30 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −3 438 | 9 500 | −26,57 | 115,00 | −395 370 | 1 092 500 |
2014-10-30 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 3 438 | 12 938 | 36,19 | 73,51 | 252 727 | 951 072 | |
2014-10-09 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −3 436 | 51 564 | −6,25 | ||||
2014-10-09 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −400 | 9 500 | −4,04 | 105,36 | −42 144 | 1 000 920 |
2014-10-09 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 134 | 9 900 | −17,73 | 104,31 | −222 598 | 1 032 669 |
2014-10-09 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −902 | 12 034 | −6,97 | 103,64 | −93 483 | 1 247 204 |
2014-10-09 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 3 436 | 12 936 | 36,17 | 73,51 | 252 580 | 950 925 | |
2014-07-17 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option |
A - Award | 27 500 | 27 500 | |||||
2014-07-17 | 3 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
19 000 | ||||||||
2014-07-17 | 3 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
19 000 | ||||||||
2014-06-17 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Stock option (right to buy) |
A - Award | 20 000 | 20 000 |